Dilution of10% now is a small price to pay for assurance AVR has the funds to drive this well into the FDA trial . This in turn will put AVR in a solid financial position when negotiating any possible acquisition as AVR would not be displaying any requirement to cut deals due to lack of available funding. Who knows how difficult it could get to find funds 12 mths ahead in this financial climate . GLTATH
Ann: Trading Halt, page-36
-
- There are more pages in this discussion • 80 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.20 |
Change
-0.200(1.09%) |
Mkt cap ! $349.8M | |||
| Open | High | Low | Value | Volume |
| $18.50 | $18.50 | $18.00 | $77.59K | 4.263K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 206 | $18.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.70 | 34 | 1 |
View Market Depth
| Last trade - 16.10pm 26/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |